What is PNH Flaer?

FLAER is an Alexa488-labeled inactive variant of aerolysin that does not cause lysis of cells. Our goals were to develop a FLAER-based assay to diagnose and monitor patients with PNH and to improve detection of minor populations of PNH clones in other hematologic disorders.

What is Flaer test?

Fluorescein-labeled proaerolysin (FLAER) is used in a flow cytometric assay to diagnose paroxysmal nocturnal hemoglobinuria (PNH). The assay takes advantage of the action of proaerolysin, a prototoxin of aerolysin, a virulence factor of the bacterium Aeromonas hydrophila.

What are the symptoms of PNH?

Overall, the most common symptoms of PNH include:

• Significant fatigue or weakness.
• Bruising or bleeding easily.
• Shortness of breath.
• Recurring infections and/or flu-like symptoms.
• Difficulty in controlling bleeding, even from very minor wounds.

What causes the hemolysis in paroxysmal nocturnal hemoglobinuria?

PNH, or Paroxysmal nocturnal hemoglobinuria, is a rare blood disease that causes red blood cells to break apart. Doctors call this breaking apart “hemolysis.” It happens because the surface of a person’s blood cells are missing a protein that protects them from the body’s immune system.

How is FLAER used in the PNH assay?

It uses a combination of several GPI-linked markers and the pan-GPI ligand, FLAER (fluorescent aerolysin), to assess granulocytes and monocytes. Additional transmembrane antigens are used to distinguish the different cell populations. Question 4. What is the sensitivity of the assay?

How is FLAER used in the diagnosis of paroxysmal hemoglobinuria ( PNH )?

Paroxysmal Nocturnal Hemoglobinuria (PNH) with FLAER (High Sensitivity) – The high sensitivity and quantitative flow cytometry assay is used in the diagnosis and follow-up of patients with paroxysmal nocturnal hemoglobinuria (PNH).

Is the fluorescent proaerolysin variant ( FLAER ) approved?

Fluorescent Proaerolysin Variant (FLAER),Fluorescent Inactive Toxin Aerolysin,PI Linked Antigen, Blood,GPI-Linked Antigen,GPI-Linked Proteins This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration.

When does LabCorp high affinity antibody test start?

Beginning on August 11, 2020, and for the next 3 months, Labcorp offers a high affinity antibody test through your doctor at no charge if you are receiving another blood test as part of an exam or treatment. If you don’t have a visit scheduled with your doctor, the Labcorp.com option (see information above) may be right for you.

https://www.youtube.com/watch?v=_N1xX49AqwQ